IGF1R and non-small cell lung carcinoma: Therefore, IGF-1R could be a potential biomarker of the drug response and clinical progression in NSCLC patients, as it was demonstrated to act as a promoter of metastasis and tumor progression in the lung tumor microenvironment [85].